Glioblastoma Stem Cells: A Neuropathologist’s View

Roger E. McLendon1 and Jeremy N. Rich2

1 Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
2 Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

Correspondence should be addressed to Roger E. McLendon, mclen001@mc.duke.edu

Received 23 August 2010; Accepted 11 October 2010

Academic Editor: Eric Deutsch

Glioblastoma (WHO Grade IV) is both the most common primary brain tumor and the most malignant. Advances in the understanding of the biology of the tumor are needed in order to obtain a clearer picture of the mechanisms driving these tumors. To neuropathologists, glioblastoma is a tumor that represents a complex system of migrating pleomorphic tumor cells, proliferating blood vessels, infiltrating inflammatory cells, and necrosis. This review will highlight how the glioma stem cell concept brings these elements together into a collective whole, interacting with microenvironmental influences in complex ways. Borrowing from chaos theory a vocabulary of “self organizing systems” and “complex adaptive systems” that seem useful in describing these pathologic features, a new paradigm of glioblastoma biology will be proposed that genetic changes should be understood in a three dimensional framework as they relate not only to the tumor cells themselves but also to the multicellular hierarchical unit, not isolated from, but responsive to, its local milieu. In this way we will come to better appreciate the impact our therapeutic interventions have on the regional phenotypic heterogeneity that exists within the tumor and the intercellular communications directing adaptation and progression.

Glioblastoma (WHO Grade IV) is both the most common primary brain tumor and the most malignant. Advances in the understanding of the biology of the tumor are needed in order to obtain a clearer picture of the mechanisms driving these tumors. The advances obtained to date have challenged those of us who work with glioblastoma on a daily basis to keep opposing ideas in our minds. For example, while glioblastoma is a uniform diagnostic category of astrocytic tumors, the intertumoral and intratumoral histologic heterogeneity within them reflects a chaotic diversity of cell types and mesenchymal backgrounds. Also, while molecular data indicate that these tumors have a hypermutable genotype [1] and many different cytologic repertoires [2, 3] available to them, recurrences often exhibit histologic features similar to the primary tumors (personal observation). What is driving the microenvironmental organization of necrosis and microvascular proliferation that these tumors recapitulate so robustly as to represent the key diagnostic features [4] of the tumor, however, is not clear. The recent identification of malignant cells within glioblastomas with stem-cell-like qualities provides insights into these questions. Furthermore the recent advances in chaos theory have provided a vocabulary of “self organizing systems” and “complex adaptive systems” that seem useful in describing these pathologic features. In order to better understand where we are now, it is useful to review some early conceptual issues related to grading malignant astrocytomas.

In the 1920s, Bailey and Cushing proposed a cytogenetic paradigm of glioblastoma classification in which a relationship between gliomas and undifferentiated cells in glioblastomas was hypothesized [5]. This immediately fell under attack as the embryologic systems had no equivalent of a glioblast. Indeed, a major problem of the cytogenetic system was that it classified glioblastomas as de novo tumors, ignoring elements of intermediate differentiation and malignant progression from lower grade tumors. Subsequently, malignant progression was approached by Kernohan [6], Ringertz [7], and Earle and colleagues [8] in a variety of ways. The major problem inherent in the cytogenetic
approach lay not only in its neglect of the nonglial features of the tumors including angiogenesis, mesenchymal elements, and even necrotic foci that have become landmarks of grading the tumor [4, 9] but also they all emphasize a linearity in progression from early tumor to later tumor that are not found in nature. Rather, the appearance of glioblastoma histology is one of explosive growth with a rapid appearance of mesenchymal features not evident in lower grade tumors. The recent description of glioma cells with stem cell qualities and mesenchymal interactions provides a nidus of organization around which accelerated growth, therapeutic resistance, and mesenchymal proliferation appear to be centered. As such, the glioma stem cells provide a potential unifying concept with which to better understand the histologic appearances of these tumors.

The concept of a malignant cell with stem cell qualities arose very early in the history of anatomic pathology as Virchow, himself, noted the similarities between certain cancers and embryogenetic processes and ascribed the origins of cancers to embryonic rests (for which proof resides in certain pediatric brain tumors [10]). Subsequently, other researchers found evidence to support the presence of a rare cell in tumors capable of regenerating the tumors and forming colonies in cell culture (reviewed in [11]). However, the origin of these purported tumor stem cells is not at all clear. In contrast to embryogenesis where the normal stem cell has a known origin from primitive precursors, the tumor stem cell origin from stem cells versus transient amplifying cells derived from stem cells versus dedifferentiated mature cells is far from being solved.

The possibility of brain tumor stem cells arose from the concepts proposed in 1982 by ML Rosenblum and colleagues who hypothesized inherent differences in the sensitivity of clonogenic cells as an explanation for clinical drug failure, tumor heterogeneity, and age-response relationships [12]. This was followed by the demonstration of complex heterogeneity in the human glioma cell line, D54, and eight-derived clones by Wikstrand and colleagues establishing heterogeneity in the human glioma cell line, D54, and eight-derived clones (reviewed in [11]). However, the origin of these purported tumor stem cells is not at all clear. In contrast to embryogenesis where the normal stem cell has a known origin from primitive precursors, the tumor stem cell origin from stem cells versus transient amplifying cells derived from stem cells versus dedifferentiated mature cells is far from being solved.

In their initial paper, Bao and colleagues found that in 2006, Bao and colleagues [24], using the CD133 antibody, selected cells from glioblastoma biopsies that were not only capable of forming tumorspheres in culture but also demonstrated self-renewal and multilineage differentiation. An immunohistochemical interrogation of these CD133+ cells further revealed the coexpression of a number of markers commonly associated with benign stem cells including SOX2, Musashi, and Nestin. The tumorspheres, when transplanted into nude mouse intracranial models, were capable of forming tumors recapitulating the glioblastoma phenotype. In contrast, the CD133 negative (CD133−) cells could neither form spheroids in normoxic conditions nor form tumors when xenografted. However, when cocultured with CD133+ cells, the CD133− cells formed tumors, the xenograft implantation rate of which was dose dependent upon the percentage of cocultured CD133+ cells. When biopsies of glioblastomas were investigated, CD133+ cells proved to be a minor population of cells varying from 1 to 3% of total tumor cell population; however, clinical studies suggested that the percentage of CD133+ cells [25, 26] or rate of tumorsphere formation [27, 28] predicted overall survival of the patient (although contrary evidence also exists [29]).

In their initial paper, Bao and colleagues found that CD133+ cells constitutively activated the DNA repair genes CHK1 and CHK2 at much higher levels than CD133− cells, and this expression mediated resistance to X-irradiation. When the checkpoint response enzymes were specifically inhibited, the CD133+ cells became as susceptible to radiation as the CD133− cells [24].

The CD133+ cells were also found to exhibit features indicative of an abrogation of programmed cell death pathways. Programmed cell death is necessary for the maintenance of a normal healthy cellular population and is
frequently implicated in cell death due to chemotherapeutic interventions. For survival, tumors must overcome natural self-destruction signals generated by these internal and external signals. In normal development, MYC drives the undifferentiated states of developing progenitor cells by combining with Max, a prodifferentiation agent. Gradually, Mad proteins displace Myc from the MYC-Mad duplex allowing the formation of Max-Mad complexes which elicit differentiation inducing signals. However, recent studies indicate that MYC proteins are overexpressed in glioma stem cells and drive not only an undifferentiated state but also trigger an antiapoptotic, prolife signaling cascade in the cells [30–32]. A prominent upstream factor stabilizing MYC complexes is the HIF2α pathway, an important pathway related to hypoxia that is discussed in more detail below [33].

Another major regulator of cell survival in GSCs is tumor necrosis factor alpha-induced protein 3 (TNFAIP3), or A20. Hjelmeland [34] determined that A20 is overexpressed in glioma stem cells relative to nonstem glioblastoma cells. Elevated levels of A20 in glioma stem cells contribute to apoptotic resistance via loss of susceptibility to TNFα-mediated apoptosis as well as decreased GSC survival, self-renewal, and tumor growth. These findings contrast to lymphomas in which loss of A20 via mutations suggests that A20 acts as a tumor suppressor. These data suggest that A20 may function as a tumor enhancer in glioma through promotion of glioma stem cell survival.

In like kind to benign neural stem cells [35], the organizational significance of rare glioblastoma cells with stem–cell-like qualities extends far beyond the confines of the cell’s cytoplasmic borders. Rather, the major organizational and adaptational impact of CD133+ cells lies in their influence on the cells and mesenchymal elements about them. Recent studies have revealed a potential amplifying feedback mechanism to be extant between CD133+ and CD133− cells involving the progrowth factor, Interleukin 6 (IL6). Recent studies by Wang and colleagues [36] indicate that the CD133− cells express IL6 but express few, if any, receptor components on their cell surface. However, the CD133+ cells express the components of IL6 receptor, gp160 and IL6 receptor alpha, on their cell surface while making less IL6 itself. The significance of IL6 lies in the fact that its signals promote STAT3 activation in GBM cells in vitro, and
targeting of either STAT3 or IL6 decreases GBM cell survival [37–40] and appears to promote invasion [41]. Additional reports also link STAT3 to stem cell biology as STAT3 is required to maintain the propagation and pluripotency of normal embryonic stem cells, neural stem cells [42–44], and glioblastoma stem cells [40, 45]. Also STAT3 has been linked to mesenchymal differentiation in glioblastoma cells, a phenotype of clinical aggressiveness and poor survival [46]. Furthermore, clinically IL6 is important as the quantitative load of IL6 and its receptors also correlate inversely with patient survival [47].

The extra-cellular influence of CD133+ cells is also manifest on the stromal cells about them. Histologically, brain tumor stem cells seem to prefer a perivascular niche [48–50], a location that recapitulates the normal neural stem cells and the vasculature of the developing central nervous system [35, 51]. Glioma stem cells have been shown to mediate vascular proliferation in glioblastomas via Vascular Endothelial Growth Factor (VEGF). VEGF is chemically activated via the Hypoxia Inducible Factor (HIF) pathway. In glioblastomas, HIF1α is found in all malignant cells, while HIF2α expression is unique to glioma stem cells. Under mild hypoxic conditions, HIF2α is stabilized preferentially while HIF is not present, leaving HIF2α as the active primary signaling agent driving the downstream expression of VEGF.

However, the hierarchical interplay between glioma stem cells and vessels is not for nutritional needs alone as the glioma stem cells have also been found to express the laminin receptor, integrin α6. This integrin is a key receptor for laminins found in the extracellular matrix (ECM) of vessels. Integrin α6 is produced in the glioma stem cells and is found to mediate growth and maintenance of glioma stem cells by knockdown studies. This is significant in that the extracellular matrix surrounding normal neural stem cells is known to provide both structural and instructive cues [52] within the CNS. Several reports have suggested that ECM structures originating from blood vessels in the adult neural stem cell germinal zones are critical in preserving their maintenance through serving as a reservoir for growth factors [53]. Thus, the potentiality of a perivascular niche rich in oncogenic signals further highlights the interplay at work among glioma stem cells, malignant nonstem glioma cells, and the mesenchymal elements earlier appreciated by Rubinstein and other pathologists. Indeed, the findings strengthen the declaration that tumors are aberrant organ systems that display a complex organizational interplay among neoplastic cells, recruited vascular, inflammatory, and stromal elements [54].

The perivascular niche is also important to stem cell physiology. Oxygen tension is tightly regulated in normal development with low oxygen tension associated with maintenance of an undifferentiated state. Hypoxia promotes the self-renewal of embryonic stem cells and prevents the differentiation of neural stem cells in vivo [55–57]. Hypoxia is also likely to be a functional component of a normal stem cell niche as well. Hematopoietic stem cells are maintained in bone marrow within hypoxic niches [58]. In regards to this, hypoxia has been shown to increase expression of stem cell markers in neuroblastomas, erythroleukemia, and cell lines [59–61]. These findings suggested to Li and colleagues [62] that the hypoxic environment of a glioblastoma may promote stem cell survival. Indeed, they found that targeting HIFs in glioma stem cells inhibited self-renewal, proliferation, and survival in vitro and attenuated tumor initiation potential of these cells in vivo. They found, as well, that HIF2α expression correlated with poor patient survival. Heddleston and colleagues [33] followed with data indicating that hypoxia promoted the self-renewal capability of the stem and nonstem population as well as promoted a more stem-like phenotype in the nonstem population. This was corroborated by increased tumorsphere formation as well as upregulation of important stem cell factors, such as OCT4, NANOG, and MYC. The importance of HIF2α was also supported via experiments demonstrating that forced expression of nondegradable HIF2α induced a cancer stem cell phenotype as well as augmented the tumorigenic potential of the nonstem population. Furthermore, HIF2α is known to mediate changes associated with clinically aggressive behavior including dissemination as well as angiogenesis. This susceptibility of the nonstem glioma population to transition to a stem-like phenotype emphasizes the importance of microenvironmental influences on the tumor and the remarkable capacity within glioma cells to adapt to hypoxia.

The multiple potentialities of a subpopulation of glioblastoma cells for self-maintenance, multilineage differentiation, and self-renewal identify them as having stem cell like qualities. However, the complex interactions among stem cells, nonstem cells, and mesenchymal cells mediate the cytologic heterogeneity well recognized by neuropathologists for decades. The presence of cells with embryonal features further lends support to these features identified by the earliest neuropathologists. The presence of vascular proliferation as a required component for grading tumors marks astrocytoma as the only tumor system in which the vascular component is a requisite feature for characterizing prognosis. Details identified by glioma stem cell researchers have characterized a more complex interaction than was previously appreciated.

Modern research makes clear that glioblastomas do not behave as an organic whole; geographic heterogeneity arises as the tumor regionally adapts to the microenvironment the individual cell clusters find themselves in (Figure 2). For example, recent studies have indicated that antiangiogenic therapy results in short-term tumor burden control but does not affect overall survival. Rather, escape mechanisms include some tumors responding with migration, producing the gliomatosis cerebri state (19567589) or responding with migration, producing the gliomatosis cerebri state (19567589). In this regard, the tumor behaves as a complex adaptive system [64] exhibiting emergent behavior. While the main body of tumor is relatively homogeneous with respect to genotype (driving genetic mutations) [65], it is heterogeneous with respect to phenotypic diversity; the offspring of glioma cells not only diverge and differentiate cytologically, but the stem-cell offspring are also driven to seek viable options. Furthermore, evidence
suggests that remnant clones of earlier stages remain as reserve cells, capable of generating tumoral renewal. Adaptational forces resulting from microenvironmental influences of hypoxia, vascularity, acidic stress, starvation, exogenous growth factors, and altered responses to endogenous growth factors as well as exogenous factors including therapeutic interventions seem to be dealt with in an ecological fashion as the offspring occupy niches.

But is the ecological model the correct model to use? How de novo tumors arise is not known. Our understanding of cancer suggests that de novo tumors arise in the same way as progressive tumors, just that the de novo tumor arises more rapidly. However, it is not clear how the many genetic mutations arise in the de novo tumors and how the tumors arise without passing through slower growing intermediate stages. In these situations of explosive growth, the whole manifests itself in a total that is greater than the sum of its parts. In other words, is ecological succession necessarily at play in these tumors or do the tumor cells escape true ecological selection via unknown, nonlinear mechanisms through which emergent glioblastoma behavior is manifest? In nonlinear systems, the end is exquisitely sensitive to initial conditions; subtle changes in starting conditions result in profoundly variable results. If this reflects reality in glioblastoma, what roles do the glioma stem cells play as tumor initiating cells?

In this regard, as anticipated by Ignatova and colleagues [17], the tumor cells have a limited repertoire of responses, limited by their overall driving genetic mutations [65] and altered epigenetic responses. However, within any cluster of cells (viewed here as a self organizing system), information flows between cells may be being nurtured by only a few glioma stem cells within their tumor-mesenchymal niche. In this system, the organotypic cell clusters are being guided not only by their own individually altered response repertoire to biological effectors (stimuli) but also by inanimate microenvironmental conditions (cues) such as access to nutrition, barriers to spread, and space to proliferate. The information supplied by the cues is subtle and can be overlooked making certain emergent properties appear to arise from mysterious origins [66]. Thus the cytotypic maps drawn by Burger and Kleihues [2] in which there is marked cytologic heterogeneity within the tumor, but relatively monotonous cellular profiles regionally, seem accessible via an understanding of microregional adaptation to both stimuli and cues. Here, we see necrosis as a reflection of failed adaptation and angiogenesis and migration as viable ones, albeit in a limited, host destructive sense. Although Darwinism may appear as the correct model, malignant progression and concomitant increased growth rates are only short-term positives as cells adapt to their micro-environments. Darwinism, strictly applied, is based on many generations of the host-agent interaction and is not the proper model.

In 2000, Hanahan and Weinberg [67] proposed six key requisites of a malignant cell: “self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis.” The tumor stem cell concept addresses the majority of these requisites in surprisingly, but biologically economical, ways. They also hypothesized, with little more than histologic evidence to guide them, that “apparently normal bystanders such as fibroblasts and endothelial cells must play key roles in driving tumor cell proliferation.” Again, the tumor stem cell concept has directly revealed mechanisms whereby these observations are supported. The findings noted above related to glioma stem cells active in their niche provide a conceptual lens through which these cell to cell and cell to stroma information signals come into focus. There are many implications for present and future research.

Many recent experiments have strived to correlate cytologic structure and expression phenotypes with
biological function. However, the histologic studies have been done on formalin-fixed, paraffin embedded tissues taken from regions, by definition, microscopically removed from the frozen section blocks from which the DNA and RNA were extracted. The data derived from glioma stem cell studies indicate that regional expression will be variable and dependent upon the micro-environment. Grinding up tissue from which to extract DNA and RNA will only provide an average answer related to the size of the tissue studied but will serve as a starting point. As data are collected from tumors relatively homogeneous with one histologic type, hypotheses can be generated to be answered by more precise methods. To address such concerns new techniques in microdissection, cell culture, and microenvironmental manipulation in xenografts will have to be developed in order to better understand the rich, organic interactions among glioma stem cells and their cellular and mesenchymal constituents.

To neuropathologists, glioblastoma has long been a tumor that represented a complex system of migrating pleomorphic tumor cells, proliferating blood vessels, infiltrating inflammatory cells, and necrosis. Now, the glioma stem cell concept brings these elements together into a collective whole interacting with microenvironmental influences in complex ways. The new paradigm of glioblastoma biology will be that genetic changes should be understood in a three-dimensional framework as they relate not only to the tumor cells themselves but also to the multicellular hierarchical unit, not isolated from, but responsive to, its local milieu. In this way we will come to better appreciate the impact our therapeutic interventions have on the regional milieu. In this way we will come to better appreciate the hierarchical unit, not isolated from, but responsive to, its tumor cells themselves but also to the multicellular three-dimensional framework as they relate not only to the tumor that represented a complex system of migrating pleomorphic tumor cells, proliferating blood vessels, infiltrating inflammatory cells, and necrosis. Now, the glioma stem cell concept brings these elements together into a collective whole interacting with microenvironmental influences in complex ways. The new paradigm of glioblastoma biology will be that genetic changes should be understood in a three-dimensional framework as they relate not only to the tumor cells themselves but also to the multicellular hierarchical unit, not isolated from, but responsive to, its local milieu. In this way we will come to better appreciate the impact our therapeutic interventions have on the regional phenotypic heterogeneity that exists within the tumor and the intercellular communications directing adaptation and progression.

References

[1] R. Martinez, V. Rohde, and G. Schackert, “Different molecular patterns in glioblastoma multiforme subtypes upon recurrence,” Journal of Neuro-Oncology, vol. 96, no. 3, pp. 321–329, 2009.

[2] P. C. Burger and P. Kleihues, “Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies,” Cancer, vol. 63, no. 10, pp. 2014–2023, 1989.

[3] T. Homma, T. Fukushima, S. Vaccarella et al., “Correlation among pathology, genotype, and patient outcomes in glioblastoma,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 9, pp. 846–854, 2006.

[4] D. N. Louis, H. Ohgaki, O. D. Weistler, and W. K. Cavenee, WHO Classification of Tumours of the Central Nervous System, IARC Press, Lyon, France, 2006.

[5] P. C. Bailey and H. Cushing, A Classification of the Tumors of the Glioma Group on a Histoegenetic Basis with a Correlated Study of Prognosis, Lippincott, Philadelphia, Pa, USA, 1926.

[6] J. W. Kernohan, R. F. Mahon, H. J. Sviene, and A. W. Adson, “A simplified classification of gliomas,” Proceedings of the Staff Meetings of the Mayo Clinic, vol. 24, pp. 71–75, 1949.

[7] N. Ringertz, “Grading of gliomas,” Acta Pathologica, Microbiologica, et Immunologica Scandinavica, vol. 27, pp. 51–64, 1950.

[8] K. M. Earle, H. E. Rentschler, and S. R. Snodgrass, “Primary intracranial neoplasm: prognosis and classification of 513 verified cases,” Journal of Neuropathology & Experimental Neurology, vol. 16, pp. 321–331, 1957.

[9] R. McLendon et al., “Glioblastoma,” in Russell and Rubinstein’s Pathology of Tumors of the Nervous System, pp. 103–130, Edward Arnold, London, UK, 2006.

[10] A. T. Yachnis, L. B. Rorke, and J. Q. Trojanowski, “Cerebellar dysplasias in humans: development and possible relationship to glial and primitive neuroectodermal tumors of the cerebellar vermis,” Journal of Neuropathology and Experimental Neurology, vol. 53, no. 1, pp. 61–71, 1994.

[11] B. J. P. Huntly and D. G. Gilliland, “Leukaemia stem cells and the evolution of cancer-stem-cell research,” Nature Reviews Cancer, vol. 5, no. 4, pp. 311–321, 2005.

[12] M. L. Rosenblum, D. V. Dougherty, C. Reese, and C. Bo Wilson, “Potentials and possible pitfalls of human stem cell analysis,” Cancer Chemotherapy and Pharmacology, vol. 6, no. 3, pp. 227–235, 1981.

[13] C. J. Wikstrand, S. H. Bigner, and D. D. Bigner, “Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies,” Cancer Research, vol. 43, no. 7, pp. 3327–3334, 1983.

[14] S. K. Singh, I. D. Clarke, M. Terasaki et al., “Identification of a cancer stem cell in human brain tumors,” Cancer Research, vol. 63, no. 18, pp. 5821–5828, 2003.

[15] T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6460, pp. 645–648, 1994.

[16] D. Bonnet and J. E. Dick, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–737, 1997.

[17] T. N. Ignatova, V. G. Kukekov, E. D. Laywell, O. N. Suslov, F. D. Vrionis, and D. A. Steinrieder, “Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro,” GLIA, vol. 39, no. 3, pp. 193–206, 2002.

[18] M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983–3988, 2003.

[19] R. Galli, E. Binda, U. Orfanelli et al., “Isolation of a cell initiating human acute myeloid leukaemia from formalin fixed, paraffin embedded tissue,” Nature, vol. 437, no. 7052, pp. 739–744, 2005.

[20] X. Yuan, J. Curtin, Y. Xiong et al., “Identification of cancer stem cells from adult glioblastoma multiforme,” Oncogene, vol. 23, no. 58, pp. 9392–9400, 2004.

[21] H. D. Hemmadi, I. Nakano, J. A. Lazareff et al., “Cancerous stem cells can arise from pediatric brain tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15178–15183, 2003.

[22] S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identification of human brain tumour initiating cells,” Nature, vol. 432, no. 7015, pp. 396–401, 2004.

[23] M. D. Taylor, H. Poppleton, C. Fuller et al., “Radial glia cells are candidate stem cells of ependymoma,” Cancer Cell, vol. 8, no. 4, pp. 323–335, 2005.
[24] S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006.

[25] M. Zhang, T. Song, L. Yang et al., “Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients,” Journal of Experimental and Clinical Cancer Research, vol. 27, no. 1, article 85, 2008.

[26] F. Zeppernick, R. Ahmadi, B. Campos et al., “Stem cell marker CD133 affects clinical outcome in glioma patients,” Clinical Cancer Research, vol. 14, no. 1, pp. 123–129, 2008.

[27] D. R. Laks, M. Masterman-Smith, K. Visnyei et al., “Neurosphere formation is an independent predictor of clinical outcome in malignant glioma,” Stem Cells, vol. 27, no. 4, pp. 980–987, 2009.

[28] E. H. Panoysyan, D. R. Laks, M. Masterman-Smith et al., “Clinical outcome in pediatric giall and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation,” Pediatric Blood & Cancer, vol. 55, no. 4, pp. 644–651, 2010.

[29] J. H. Phi, S.-H. Park, C. K. Chung, K.-C. Wang, B.-K. Cho, and S.-K. Kim, “Atypical cell clusters expressing both neuronal and oligodendrocytic markers: novel histological pattern of glioneuronal tumors?: case report,” Pathology International, vol. 59, no. 10, pp. 735–743, 2009.

[30] H. Zheng, H. Ying, H. Yan et al., “Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma,” Cold Spring Harbor Symposium on Quantitative Biology, vol. 73, pp. 427–437, 2008.

[31] H. Zheng, H. Ying, H. Yan et al., “p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation,” Nature, vol. 455, no. 7216, pp. 1129–1133, 2008.

[32] J. Wang, H. Wang, Z. Li et al., “c-Myc is required for maintenance of glioma cancer stem cells,” PLoS ONE, vol. 3, no. 11, article e3769, 2008.

[33] J. M. Heddleston, Z. Li, R. E. McLendon, A. B. Hjelmeland, and J. N. Rich, “The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype,” Cell Cycle, vol. 8, no. 20, pp. 3274–3284, 2009.

[34] A. B. Hjelmeland, Q. Wu, S. Wickman et al., “‘Argentic’ A20 decreases glioma stem cell survival and tumor growth,” Cell, vol. 8, no. 2, pp. 57–70, 2010.

[35] J. H. McCarty, “Cell adhesion and signaling networks in brain neurovascular units,” Current Opinion in Hematology, vol. 16, no. 3, pp. 209–214, 2009.

[36] H. Wang, J. D. Lathia, Q. Wu et al., “Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth,” Stem Cells, vol. 27, no. 10, pp. 2393–2404, 2009.

[37] S. O. Rahaman, P. C. Harbor, O. Chernova, G. H. Barnett, M. A. Vogelbaum, and S. J. Haque, “Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells,” Oncogene, vol. 21, no. 55, pp. 8404–8413, 2002.

[38] L. Konnikova, M. Kotecki, M. M. Kruger, and B. H. Cochran, “Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells,” BMC Cancer, vol. 3, article 23, 2003.

[39] J. Gu, G. Li, T. Sun et al., “Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells,” Journal of Neuro-Oncology, vol. 89, no. 1, pp. 9–17, 2008.

[40] C. Villalva et al., “STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?” International Journal of Cancer. In press.

[41] G.-H. Li, H. Wei, S.-Q. Lv, H. Ji, and D.-L. Wang, “Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells,” International Journal of Oncology, vol. 37, no. 1, pp. 103–110, 2010.

[42] D. R. Hodge, E. M. Hurt, and W. L. Farrar, “The role of IL-6 and STAT3 in inflammation and cancer,” European Journal of Cancer, vol. 41, no. 16, pp. 2502–2512, 2005.

[43] T. Matsuda, T. Nakamura, K. Nakao et al., “STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells,” EMBO Journal, vol. 18, no. 15, pp. 4261–4269, 1999.

[44] H. Niwa, T. Burdon, J. Chambers, and A. Smith, “Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3,” Genes and Development, vol. 12, no. 13, pp. 2048–2060, 1998.

[45] M. M. Sherry, A. Reeves, J. K. Wu, and B. H. Cochran, “STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells,” Stem Cells, vol. 27, no. 10, pp. 2383–2392, 2009.

[46] M. S. Carro, W. K. Lim, M. J. Alvarez et al., “The transcriptional network for mesenchymal transformation of brain tumours,” Nature, vol. 463, no. 7279, pp. 318–325, 2010.

[47] P. Birner, K. Tsumanglava-Uzeir, S. Natchev, and M. Guentchev, “STAT3 tyrosine phosphorylation influences survival in glioblastoma,” Journal of Neuro-Oncology, vol. 100, no. 3, pp. 339–343, 2010.

[48] S. Bao, Q. Wu, S. Sathornsumetee et al., “Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor,” Cancer Research, vol. 66, no. 16, pp. 7843–7848, 2006.

[49] C. Calabrese, H. Poppleton, M. Kocak et al., “A perivascular niche for brain tumor stem cells,” Cancer Cell, vol. 11, no. 1, pp. 69–82, 2007.

[50] Q. Shen, Y. Wang, E. Kokovay et al., “Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions,” Cell Stem Cell, vol. 3, no. 3, pp. 289–300, 2008.

[51] M. Tavazoie, L. Van der Veken, V. Silva-Vargas et al., “A specialized vascular niche for adult neural stem cells,” Cell Stem Cell, vol. 3, no. 3, pp. 279–288, 2008.

[52] J. D. Lathia, B. Patton, D. M. Eckley et al., “Patterns of laminins in the extracellular niche of mouse embryonic stem cells: a potential for targeted therapy?” Journal of Experimental and Clinical Cancer Research, vol. 27, no. 4, pp. 69–70, 2008.

[53] A. Kerever, J. Schnack, D. Vellinga et al., “Novel extracellular matrix structures in the neural stem cell niche capture the neurogenic factor fibroblast growth factor 2 from the extracellular milieu,” Stem Cells, vol. 27, no. 10, pp. 2383–2392, 2009.

[54] J. D. Lathia, B. Patton, D. M. Eckley et al., “Patterns of laminins in the extracellular niche of mouse embryonic stem cells: a potential for targeted therapy?” Journal of Experimental and Clinical Cancer Research, vol. 27, no. 4, pp. 69–70, 2008.
[57] M. C. Simon and B. Keith, “The role of oxygen availability in embryonic development and stem cell function,” Nature Reviews Molecular Cell Biology, vol. 9, no. 4, pp. 285–296, 2008.

[58] K. Parmar, P. Mauch, J.-A. Vergilio, R. Sackstein, and J. D. Down, “Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 13, pp. 5431–5436, 2007.

[59] A. Jögi, I. Øra, H. Nilsson et al., “Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 10, pp. 7021–7026, 2002.

[60] T. T. Tavaluc, L. T. Hart, D. T. Dicker, and W. S. El-Deiry, “Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines,” Cell Cycle, vol. 6, no. 20, pp. 2554–2562, 2007.

[61] S. Giuntoli, E. Rovida, A. Gozzini et al., “Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells,” Stem Cells, vol. 25, no. 5, pp. 1119–1125, 2007.

[62] Z. Li, S. Bao, Q. Wu et al., “Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells,” Cancer Cell, vol. 15, no. 6, pp. 501–513, 2009.

[63] T. T. Batchelor, A. G. Sorensen, E. di Tomaso et al., “AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients,” Cancer Cell, vol. 11, no. 1, pp. 83–95, 2007.

[64] E. D. Schwab and K. J. Pienta, “Cancer as a complex adaptive system,” Medical Hypotheses, vol. 47, no. 3, pp. 235–241, 1996.

[65] S. Nobusawa, J. Lachuer, A. Wierinckx et al., “Intratumoral patterns of genomic imbalance in glioblastomas,” Brain Pathology, vol. 20, no. 5, pp. 936–944, 2010.

[66] S. Camazine, J. Deneubourg, N. R. Franks, J. Sneyd, G. Theraulaz, and E. Bonabeau, Self-Organization in Biological Systems, Princeton University Press, Princeton, NJ, USA, 2001.

[67] D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.